Pharsight

Amrix is owned by Teva Pharms Intl.

Amrix contains Cyclobenzaprine Hydrochloride.

Amrix has a total of 8 drug patents out of which 0 drug patents have expired.

Amrix was authorised for market use on 01 February, 2007.

Amrix is available in capsule, extended release;oral dosage forms.

Amrix can be used as relief of muscle spasm.

The generics of Amrix are possible to be released after 26 February, 2025.

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7829121	TEVA PHARMS INTL	Modified release dosage forms of skeletal muscle relaxants	Nov, 2023 (9 months from now)
US9375410	TEVA PHARMS INTL	Modified release dosage forms of skeletal muscle relaxants	Nov, 2023 (9 months from now)
US9399025	TEVA PHARMS INTL	Modified release dosage forms of skeletal muscle relaxants	Nov, 2023 (9 months from now)
US8877245	TEVA PHARMS INTL	Modified release dosage forms of skeletal muscle relaxants	Nov, 2023 (9 months from now)
US7544372	TEVA PHARMS INTL	Modified release dosage forms of skeletal muscle relaxants	Nov, 2023 (9 months from now)
US7820203	TEVA PHARMS INTL	Modified release dosage forms of skeletal muscle relaxants	Nov, 2023 (9 months from now)
US7790199	TEVA PHARMS INTL	Modified release dosage forms of skeletal muscle relaxants	Nov, 2023 (9 months from now)
US7387793	TEVA PHARMS INTL	Modified release dosage forms of skeletal muscle relaxants	Feb, 2025 (2 years from now)